Anaspec has announced the release of a recombinant human BAFF protein.
Naive B-cells, treated with 20ng/ml to 1,000ng/ml BAFF protein, prepared by Anaspec, have been showing increased IgG secretion compared with two commercial sources.
BAFF (BlyS, Tall-1, Thank, TNFSF13B and zTNF4) belongs to the TNF range of proteins and is expressed by myeloid cells.
It is a 285-amino-acid-long type-II transmembrane protein, with the soluble 152-amino-acid-active region.
BAFF plays a pivotal role in B-cells homeostasis, including the survival of immature B-cells and the transition of B-lymphocytes from T1 to T2 stage, and causes an increase in antibody secretion by B-cells.
The sequence (accession number NP_006564) corresponding to the extracellular domain of human BAFF along with a 6x His tag was expressed in E.coli.
Recombinant human BAFF was purified from urea-denatured bacterial lysate using immobilised metal affinity chromatography (IMAC) and refolded into its active state using a proprietary technique.
The molecular weight of the recombinant human BAFF is 17.2kDa.
Containing less than 0.1 EU of endotoxin per 1ug of protein as determined by a LAL assay, the activity of BAFF was determined by its ability to stimulate the production of immunoglobulin molecules such as IgG, IgA and IgM in isolated mouse B-lymphocytes.
Purified recombinant human BAFF is supplied as sterile and frozen at 0.1mg/ml in 1x PBS buffer with 5mM DTT, pH=7.5.
